5 Tips about Sifalimumab You Can Use Today
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage numerous intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Key trial goals were being to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis